DalsnaFinance › Analyst accuracy › BTIG › GANX target
BTIG reiterates Buy on Gain Therapeutics stock on trial data
BTIG reiterated a Buy rating and $5.00 price target on Gain Therapeutics
A fact about what BTIG published, as reported by Investing.com, not a recommendation from Dalsna Finance; BTIG is not affiliated with this site.
Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.